THE SAFETY AND TOLERABILITY OF OPZELURA—A TOPICAL JAK INHIBITOR

  • Discontinuation due to TEAEs with OPZELURA vs vehicle: 0.8% with OPZELURA vs 3.2% with vehicle in TRuE-AD1 and TRuE-AD22
  • Adverse reactions occurring in <1% for OPZELURA vs 0% for vehicle were neutropenia, allergic conjunctivitis, pyrexia, seasonal allergy, herpes zoster, otitis externa, staphylococcal infection, and acneiform dermatitis1
  • Low rate of application site reactions such as burning (0.8% with OPZELURA vs 4.4% with vehicle) and pruritus (0% with OPZELURA vs 2.4% with vehicle)2

Learn about dosing and administration >

JAK=Janus kinase; TEAE=treatment-emergent adverse event.

References: 1. Opzelura. Prescribing Information. Incyte Corporation; 2021. 2. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. Published online May 3, 2021. doi:10.1016/j.jaad.2021.04.085.